<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To assess therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>) risk in patients treated for Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) on successive generations of Stanford clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> treated at Stanford with at least 5 years of follow-up after completing therapy were identified from our database </plain></SENT>
<SENT sid="2" pm="."><plain>Records were reviewed for outcome and development of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Seven hundred fifty-four patients treated from 1974 to 2003 were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Therapy varied across studies </plain></SENT>
<SENT sid="5" pm="."><plain>Radiotherapy evolved from extended fields (S and C studies) to involved fields (G studies) </plain></SENT>
<SENT sid="6" pm="."><plain>Primary chemotherapy was <z:chebi fb="0" ids="28925">mechlorethamine</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, procarbazine, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (MOPP) or procarbazine, <z:chebi fb="0" ids="28925">mechlorethamine</z:chebi>, and vinblastine (PAVe) in S studies; MOPP, PAVe, vinblastine, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (VBM), or <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, vinblastine, and <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> (ABVD) in C studies; and VbM (reduced dose of <z:chebi fb="0" ids="3139">bleomycin</z:chebi> compared with VBM) or <z:chebi fb="0" ids="28925">mechlorethamine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, vinblastine, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (Stanford V) in G studies </plain></SENT>
<SENT sid="7" pm="."><plain>Cumulative exposure to <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> (AA) was notably lower in the G studies compared with the S and C studies, with a 75% to 83% lower dose of <z:chebi fb="0" ids="28925,37598">nitrogen mustard</z:chebi> in addition to omission of procarbazine and melphalan </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-four (3.2%) of 754 patients developed t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>, 15 after primary chemotherapy and nine after salvage chemotherapy for relapsed <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The incidence of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> was significantly lower in the G studies (0.3%) compared with the S (5.7%) or C (5.2%) studies (P &lt; .001) </plain></SENT>
<SENT sid="10" pm="."><plain>Additionally, in the G studies, no t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> was noted after primary therapy, and the only patient who developed t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> did so after second-line therapy </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Our data demonstrate the relationship between the cumulative AA dose and t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Limiting the dose of AA and decreased need for secondary treatments have significantly reduced the incidence of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>, which was extremely rare in the G studies (Stanford V era) </plain></SENT>
</text></document>